hydrochlorothiazide · Novitium Pharma · NDA 219141
Inzirqo
Earliest generic entry, as listed
23 Jan 2044
Blocked by patent: US 11878022.
Listed patents · 1 unexpired
2 Orange Book listing rows for 1 patent. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11878022 | drug product, use U-4138, U-4139 | 23 Jan 2044 |
| US 11878022 listing row | drug product, use U-4138 · sets the listed date | 23 Jan 2044 |
| US 11878022 listing row | drug product, use U-4139 · sets the listed date | 23 Jan 2044 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219141 · 001 · RLD | for suspension, oral | 10MG/ML | 23 Jan 2044 |